

Studienübersicht

Tumor Zentrum Aargau

Studienkoordination

Tumor Zentrum Aargau
Hirslanden Medical Center
Rain 34
CH – 5000 Aarau
Phone: +41 62 836 78 43
E-Mail: studien@tumor-zentrum.ch

Klinische Forschung - Tumor Zentrum Aargau

Klinische Studien dienen dazu, die Wirksamkeit und Sicherheit neuer Verfahren oder Medikamente zu prüfen sowie bekannte Behandlungsmodelle zu optimieren.

Das Ärzte- und Pflegeteam am Tumor Zentrum beteiligt sich seit vielen Jahren regelmässig an wissenschaftlichen Forschungsprojekten und engagiert sich aktiv in nationalen und internationalen Netzwerken und Fachgesellschaften wie dem Swiss Tumor Institute, der Schweizer Arbeitsgemeinschaft für klinische Krebsforschung (SAKK) sowie europäischen und amerikanischen Krebsgesellschaften (z. B. ESMO & ASCO, DGHO, ESH & ASH).

Dadurch sind wir in der Lage, unseren PatientInnen zu jedem Zeitpunkt eine qualitätsgesicherte kontinuierliche medizinische Versorgung auf höchstem Niveau zu gewährleisten und setzen damit Massstäbe für eine integrierte, ganzheitliche, interdisziplinäre Behandlung – ambulant und stationär.

Brustkrebs (1/2)

Studie	Phase	Indikation/Beschreibung
Vision	NA	Intelligent Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial
Fourlight-2 C4391025	II	An interventional, open-label, randomized, multicenter, phase 2 study of PF-07220060 plus Letrozole compared to Letrozole alone in postmenopausal women 18 years or older with hormone receptor-positive, HER2-negative breast cancer in the neoadjuvant setting
Elegant	III	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
RIBELLE	NIS	RIB-ELLE: A non-interventional study to assess the safety and efficacy of RIBociclib in combination with an aromatase inhibitor (letrozole, anastrozole, exemestane) in the swiss advanced breast cancer population

- schwarz: Rekrutierung offen
- grau: Studienpatienten im follow up

Brustkrebs (2/2)

Studie	Phase	Indikation/Beschreibung
GO42784 - LidERA	III	A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer
VERITAC-3 C4891002	III	A phase 3, randomized, double-blind, multicenter study of ARV-471 (PF-07850327) plus Palbociclib vs Letrozole plus Palbociclib for the treatment of participants with estrogen receptor-positive, HER2-negative breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease (VERITAC-3)
SAKK 96/12	III	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial

- **schwarz:** Rekrutierung offen
- **grau:** Studienpatienten im follow up

Urologische Tumoren

Studie	Phase	Indikation/Beschreibung
SAKK 08/23	II	Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
SAKK 96/12	III	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial

- schwarz: Rekrutierung offen
- grau: Studienpatienten im follow up

Gastrointestinale Tumoren

Studie	Phase	Indikation/Beschreibung
DANTE	III	A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial
DANTE	II	A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039) - The DANTE Trial

- schwarz: Rekrutierung offen
- grau: Studienpatienten im follow up

Diverse Indikationen

Studie	Phase	Indikation/Beschreibung
OvCar	Register	A retrospective and prospective registry of patients with ovarian cancer
LuCa2	Register	Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations
EORTC 1553 SPECTA	Register	SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

- schwarz: Rekrutierung offen
- grau: Studienpatienten im follow up

Geschlossene Studien Brustkrebs (1/4)

Studie	Phase	Indikation/Beschreibung
IBCSG 24/02 - SOFT	III	A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer
SAKK 24/09	III	Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial
TANIA - MO22998	III	A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment
SAKK 24/06	II	Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial.
IBCSG 22/00	III	Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer

Geschlossene Studien Brustkrebs (2/4)

Studie	Phase	Indikation/Beschreibung
SAKK 22/10	II	A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer
3144A2 3005	II	A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer
IBCSG 35/07 SOLE	III	A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer
MonaLEEs7	III	A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
3144A2-3004-WW / B1891004	III	A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer

Geschlossene Studien Brustkrebs (3/4)

Studie	Phase	Indikation/Beschreibung
SafeHer - MO28048	III	A phase III prospective two-cohort nonrandomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable HER2-positive early breast cancer [SafeHer Study]
MonaLEESa3	III	MONALEESA-3: A randomized double-blind, placebocontrolled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment
SAKK 95/17	III	SAKK 95/17: A 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy. A multicenter randomized phase III trial.
CBYL719C2401	NA	A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer
EORTC 1617	NA	Follow-up in Early and Locally Advanced Breast Cancer Patients (non metastatic) - QoL

Geschlossene Studien Brustkrebs (4/4)

Studie	Phase	Indikation/Beschreibung
EPIK-B3	III	EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation
IBCSG-Impassion030	III	A phase 3, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1-antibody) in combination with standard adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

Geschlossene Studien Urologische Tumoren

Studie	Phase	Indikation/Beschreibung
Seqond	Registry	QoL in 2nd line therapy
TAK-700 - C21004	III	A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
212082PCR4001	Registry	A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer
Stampede	II/III	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy A multi-arm multi-stage randomized controlled trial

Geschlossene Studien Gastrointestinale Tumoren (1/2)

Studie	Phase	Indikation/Beschreibung
SAKK 41/03	I/II	Oxaliplatin, irinotecan and capecitabine as a combination regimen for first line treatment of advanced or metastatic colorectal cancer. A multicenter phase I-II trial
SAKK 76/02	II	Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
SAKK 41/07	II	Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial
SAKK 41/06	III	Bevacizumab maintenance versus no maintenance after stop of first-line chemotherapy in patients with metastatic colorectal cancer. A randomized multicenter phase III non-inferiority trial.
ML18147	III	A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination.
SAKK 41/14 - Active2	III	Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial.

Geschlossene Studien Gastrointestinale Tumoren (2/2)

Studie	Phase	Indikation/Beschreibung
MAVERICC ML25710	II	A randomized Phase II study of Bevacizumab/mFOLFOX6 vs Bevacizumab/ mFOLFOFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer
QuoliTrap	IV	Beobachtungsstudie zur Erfassung der Lebensqualität bei Patienten mit metastasiertem kolorektalem Karzinom unter Zaltrap® Therapie (QoLiTrap)
I4T-MC-JVDD	IV	Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry
CA224-123	III	A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

Geschlossene Studien Lunge

Studie	Phase	Indikation/Beschreibung
NEXT - EMR 062 240-506	IIIb	Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m ² weekly and 500 mg/m ² every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC)
M11-089	III	Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Geschlossene Studien Diverse Indikationen (1/2)

Studie	Phase	Indikation/Beschreibung
START		Swiss Taxotere Alopecia Prevention Trial
BEVLIN - MO21609	II	An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma
SOMPAS - 20070626		A prospective non-interventional evaluation of the management of symptomatic anemia in patients receiving myelotoxic chemotherapy for colorectal cancer, breast cancer and lung cancer in Switzerland
Proskin		Prospective, observational practice survey of applied skin care and management of Cetuximab related skin reactions
MENAC		A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing chemotherapy.
SAKK 35/14	II	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.

Geschlossene Studien Diverse Indikationen (2/2)

Studie	Phase	Indikation/Beschreibung
FN01 MASCC Survey	observational	Predicting febrile neutropenia occurrence in adult patients treated with chemotherapy for a solid tumor (or a Hodgkin's/non-Hodgkin's lymphoma) with an expected moderate risk of febrile neutropenia according to published guidelines (10% to 20%): a MASCC survey
Consilium	observational	Efficiency of the "Consilium" smartphone app for detecting symptoms and treatment side effects in cancer patients depending on form of medication application, age and outpatient characteristics: observational study
SAKK 80/19	registry	Alpine Tumor Immunology Registry